Evidence map›Paper›PMID 32451972›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer.

A S Algebaly, R S Suliman, W S Al-Qahtani

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Heliyon · 2024
    Article
  4. GermlineFrontiers in medicine · 2024
    Article
  5. The Clinical Significance of Genetic Variation in Ovarian Cancer.International journal of molecular sciences · 2023
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

A S AlgebalyBiology Department, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
R S SulimanBiology Department, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
W S Al-QahtaniBiology Department, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia. info@drwedad.com.ORCID http://orcid.org/0000-0002-7347-9804

Funding

Princess Nourah Bint Abdulrahman University (SA) 34-k-47
6 · The paper itself

Abstract

backgroundAbout 5-10% of incidences of breast cancers have been reported as a result of germline mutations of BRCA genes. However, the mutational spectrum of BRCA1 and BRCA2 genes among breast cancer Saudi women patients is inadequate at present. Therefore, the present study aimed to report the specific germinal mutation of BRCA1 and BRCA2 in the entire coding regions, to investigate the prevalence rate of BRCA1 & BRCA2 mutations among Saudi women and the effect of these mutations, both benign and malignant tumors. METHODOLOGY: A total of 270 tissue samples of benign and malignant breast tumors were collected from Saudi women patients, Riyadh, Saudi Arabia. Examination of BRCA1 and BRCA2 germline mutations was performed using heteroduplex DNA analysis (HDA) or single-stranded conformation analysis (SSCA). 177 breast cancer women with malignant tumors and 93 with benign tumors were enrolled in the study. A total of 62 out of 177 breast cancer patients carried a BRCA1 or BRCA2 mutation (54 BRCA1 and 8 BRCA2). The analysis was done using the Sanger sequence assay.

resultsPoint and frameshift mutations through the entire coding area of the two genes indicated that all the mutations were germline alterations and of early-onset breast cancers. The mean ages of diagnosed breast cancer women for BRCA1 and BRCA2 mutation carriers were 36.3 (± 3.5) and 37.9 (± 3.7) years, whereas that of benign control was 35(± 2.5) years.

conclusionPoint and frameshift mutations across the entire coding region of BRCA1 and BRCA2 are responsible for many breast cancers cases.

Indexed as

Genes, BRCA1Genes, BRCA2Germ-Line MutationAdultBreast NeoplasmsFemaleFrameshift MutationGenetic CodeHumansPoint MutationSaudi ArabiaBRCA1BRCA2Breast cancerGermline mutationsHeteroduplex DNA analysisNovel mutationsRiyadhSanger sequencing

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.